Clinical Trial Update: Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 dose-range finding trial of candesartan (Atacand) in children aged 6 to under 17 with hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Atacand (candesartan)

Snippet

Sponsor: AstraZeneca | Conditions: Pediatric Hypertension | Phase 3 | Status: COMPLETED